Why Novartis lost its treatment dispute with Teva

In a patent revocation and infringement counterclaim action between Teva and Novartis, His Honour Judge Richard Hacon found, in a decision handed down on November 10 2022, lack of inventive step with respect to two Novartis formulation patents ( EP 2,964,202 and EP 3,124,018)

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

Why Novartis lost its treatment dispute with Teva

More on this story

Editor's picks

Editor's picks

More features